| アブストラクト | OBJECTIVE: To evaluate the relation between penicillin allergy and development of meticillin resistant Staphylococcus aureus (MRSA) and C difficile. DESIGN: Population based matched cohort study. SETTING: United Kingdom general practice (1995-2015). PARTICIPANTS: 301 399 adults without previous MRSA or C difficile enrolled in the Health Improvement Network database: 64 141 had a penicillin allergy and 237 258 comparators matched on age, sex, and study entry time. MAIN OUTCOME MEASURES: The primary outcome was risk of incident MRSA and C difficile. Secondary outcomes were use of beta lactam antibiotics and beta lactam alternative antibiotics. RESULTS: Among 64 141 adults with penicillin allergy and 237 258 matched comparators, 1365 developed MRSA (442 participants with penicillin allergy and 923 comparators) and 1688 developed C difficile (442 participants with penicillin allergy and 1246 comparators) during a mean 6.0 years of follow-up. Among patients with penicillin allergy the adjusted hazard ratio for MRSA was 1.69 (95% confidence interval 1.51 to 1.90) and for C difficile was 1.26 (1.12 to 1.40). The adjusted incidence rate ratios for antibiotic use among patients with penicillin allergy were 4.15 (95% confidence interval 4.12 to 4.17) for macrolides, 3.89 (3.66 to 4.12) for clindamycin, and 2.10 (2.08 to 2.13) for fluoroquinolones. Increased use of beta lactam alternative antibiotics accounted for 55% of the increased risk of MRSA and 35% of the increased risk of C difficile. CONCLUSIONS: Documented penicillin allergy was associated with an increased risk of MRSA and C difficile that was mediated by the increased use of beta lactam alternative antibiotics. Systematically addressing penicillin allergies may be an important public health strategy to reduce the incidence of MRSA and C difficile among patients with a penicillin allergy label. |
|---|
| 組織名 | Division of Rheumatology, Allergy, and Immunology, Department of Medicine,;Massachusetts General Hospital, Boston, MA 20114, USA kblumenthal1@partners.org.;Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA,;USA.;Harvard Medical School, Boston, MA, USA.;Massachusetts General Hospital, Boston, MA 20114, USA.;Division of Infectious Diseases, Department of Medicine, Massachusetts General;Hospital, Boston, MA, USA. |
|---|
